All In Biotech

Drug Trial Radar · NCT06239155

A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors

Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of AST-3424 in Treatment of Patients With Advanced Solid Tumors and Its Correlation With AKR1C3 Enzyme Expression

Last checked: Nov 19, 2026Latest source record: Feb 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

51

Planned (sponsor's estimate)

Start

Sep 3, 2019

Primary completion

Nov 30, 2025

Study completion Nov 30, 2025

Sponsor

Sponsor type
Industry
First posted
Feb 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of AST-3424 administered as a single agent

Conditions

  • Advanced Solid Tumors
  • Hepatocellular Carcinoma

Interventions

  • AST-3424Drug

    liquid formulation for Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events(AEs)Time frame: measure begins from informed consent to 30 days after last dose of study drug.
  2. Safety changes in electrocardiogram (ECG)Time frame: Day 1 Cycles 1 and 2 (each cycle is 21 days)
  3. Safety Changes of body weightTime frame: Day 1 of each cycle (there are 34 cycles; 21 days for each cycle)
  4. Dose limiting toxicities (DLTs) in phase ITime frame: Throughout Cycle 1 (21 days for each cycle) in phase I (dose escalation phase).
  5. Maximum Tolerated Dose(MTD)/Recommended Phase 2 Dose (RP2D) in phase ITime frame: Day 1 and Day 8 of each cycle (all 34 cycles and there are 21 days for each cycle)
  6. Pharmacokinetics (PK) - Time to maximum concentration (Tmax)Time frame: Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)
  7. PK - Maximum peak plasma concentration (Cmax)Time frame: Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)
  8. PK - The magnitude of the slope of the linear regression of the log concentration vs. time profile during the terminal phase (Kel)Time frame: Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)
  9. PK - Half-life (T1/2)Time frame: Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)
  10. PK - Area under the concentration-time curve (AUClast)Time frame: Days 1 and 8 of Cycle 1(first cycle of 34 cycles and there are 21 days for each cycle)
  11. Objective response rate(ORR)Time frame: Approximately 36 months
  12. Disease control rate(DCR)Time frame: Approximately 36 months
  13. Duration of response (DOR)Time frame: Approximately 36 months
  14. Progress free survival (PFS)Time frame: Approximately 36 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Guangdong Qifu Hospital

    Guangzhou, Guangdong, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Chinese People's Liberation Army Eastern Theater General Hospital Qinhuai medical District

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of China Medical University

    Shenyang, Liaoning, China

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China

  • Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.